For some patients, a noticeable difference in facial volume can appear within the first three to four months of starting the medication, particularly if they lose 10% to 15% of their body weight during that initial window
In clinical trials, Retatrutide has been studied as a once-weekly subcutaneous injection
And so even at a lower unit cost, it may still be the case that the volume of these agents, may drive significant expense for an employer and really need the expertise of a clinic like VITAS to ensure that only the right patients are getting treated with these, drugs at the right time and for the right indication
Summary: Clinical studies demonstrate an overall favorable safety profile, low risk for hypoglycemia, weight neutrality, primarily nonrenal clearance, and efficacy for glycosylated hemoglobin reduction, typically ranging from 0.6% to 0.8% depending on baseline levels